ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1451

Starting of Biological Dmards May be Postponed in RA Patients with Multimorbidity: Single Centre Real Life Results

Berkan Armagan1, Alper Sari1, Abdulsamet Erden1, Levent Kilic1, Efe Cem Erdat2, Omer Karadag3, Ali Akdogan1, Sule Apras Bilgen3, Ihsan Ertenli3, Sedat Kiraz1 and Umut Kalyoncu1,3, 1Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, 2Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey, 3Department of Internal Medicine, Divison of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biologic drugs, Comorbidity and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

RA is a burdensome for most of the patients, comorbidities usually provide additional disadvantags the course of RA. The possible effects of comorbidities on selection of biological DMARDs in RA patients were not frequently assessed.

Objectives: The objective of this study was to assess effects of comorbidities and multimorbidities on biological DMARDs choose, timing of biological DMARDs and response of biological DMARDs.

Methods:

Hacettepe University Biologic Registry (HUR-BIO) is single center biological DMARD registry. After 2012, all known comorbidities reported by patients were evaluated by a standard questionnaire. HUR-BIO included 1235 patients with RA and 998 patients were assessed for comorbidities. Assessed comorbidities were obesity, diabetes, hypertension, hyperlipidemia, osteoporosis, coronary heart disease, cerebrovascular event, chronic kidney disease, hepatitis B, tuberculosis, amyloidosis, and cancer. Multimorbidity defined as more than 1 comorbidity. Disease duration, initial date of biological DMARDs, initial and overall biological DMARD choose were recorded. DAS-28 responses were compared to comorbidity presence and multimorbidity.

Results:

Totally, 998 RA patients were enrolled. The mean age was 53.1 (12.5) and mean disease duration (SD) was 11.7 (7.5) years. At least one comorbidity was detected in 689 (69.1%) patients, 375 (37.9%) patients had multimorbidity. Patients had mean 1.36 ± 1.32 comorbidity. Patients with comorbidity were older (56.2 ± 11.3 vs 46.1 ± 12.4, p<0.001), more frequently female (83% vs 74%, p=0.01), worst functional disability (HAQ score 1.0 (0-2.9), vs 0.77 (0-2.5), p<0.001) and highest baseline patient global assessment score (70 (0-100) vs 60 (10-100), p=0.004). The median duration of first biological DMARDs prescription were 60 (3-552) months after RA diagnosis. For multimorbidity patients, the median first biological prescription duration were longer than patients without multimorbidity patients (72 (3-552) vs 60 (3-396) months, p<0.001). The physicians prescribe anti-TNF biological drugs less frequently than other biologic DMARDs in patients with at least one comorbidity (66.2% vs 74.5%, p=0.007) or multimorbidity (34.6% vs. 43.5%, p=0.006). Patients with comorbidities and multimorbidity achieved to DAS-28 remission less frequently than patients without comorbidity (31.6% vs 42.6%, p=0.012 and 27.2% vs 39.7%, p=0.001, respectively).

Conclusion:

Physicians were postpone to prescribe biological DMARDs in patients with multimorbidity. Furthermore, comorbidity may have a negative effect on the treatment response. This situation may rise from both late start of the efficient treatment and additional burden effect of the comorbidities on the course of RA disease.


Disclosure: B. Armagan, None; A. Sari, None; A. Erden, None; L. Kilic, None; E. C. Erdat, None; O. Karadag, None; A. Akdogan, None; S. Apras Bilgen, None; I. Ertenli, None; S. Kiraz, None; U. Kalyoncu, None.

To cite this abstract in AMA style:

Armagan B, Sari A, Erden A, Kilic L, Erdat EC, Karadag O, Akdogan A, Apras Bilgen S, Ertenli I, Kiraz S, Kalyoncu U. Starting of Biological Dmards May be Postponed in RA Patients with Multimorbidity: Single Centre Real Life Results [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/starting-of-biological-dmards-may-be-postponed-in-ra-patients-with-multimorbidity-single-centre-real-life-results/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/starting-of-biological-dmards-may-be-postponed-in-ra-patients-with-multimorbidity-single-centre-real-life-results/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology